3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
6
Carcinoma, Hepatocellular
4
Sarcoma
2
Rectal Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Gastrointestinal Stromal Tumors
2
Solid Malignant Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Piebaldism
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Glioblastoma
1
Disease Progression
1
Cholangiocarcinoma
1
Bone Neoplasms
1
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
regorafenib
×
90 days
×
Clear all
No trials found.